Subhadip Mukhopadhyay

Dr. Subhadip Mukhopadhyay

Department of Radiation Oncology, Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2023 in Science Advances
Verified
Journal Article
Open access
SMSubhadip Mukhopadhyay
Subhadip Mukhopadhyay
JEJoel Encarnación-Rosado
Joel Encarnación-Rosado
ELElaine Y. Lin
Elaine Y. Lin
ASAlbert S. W. Sohn
Albert S. W. Sohn
HZHuan Zhang
Huan Zhang
AKAlec C. Kimmelman
Alec C. Kimmelman
Pancreatic ductal adenocarcinoma (PDAC) cells maintain a high level of autophagy, allowing them to thrive in an austere microenvironment. However, the processes through which autophagy promotes PDAC growth and survival are still not fully understood. Here, we show that autophagy inhibition in PDAC alters mitochondrial function by losing succinate dehydrogenase complex iron sulfur subunit B expression by limiting the availability of the labile iron pool. PDAC uses autophagy to maintain iron homeostasis, while other tumor types assessed require macropinocytosis, with autophagy being dispensable. We observed that cancer-associated fibroblasts can provide bioavailable iron to PDAC cells, promoting resistance to autophagy ablation. To overcome this cross-talk, we used a low-iron diet and demonstrated that this augmented the response to autophagy inhibition therapy in PDAC-bearing mice. Our work highlights a critical link between autophagy, iron metabolism, and mitochondrial function that may have implications for PDAC progression.

18 February 2026 in Life Sciences
Verified
Journal Article
Closed access
FNFahika Nazeerulla
Fahika Nazeerulla
IBIshani Banerjee
Ishani Banerjee
MPManash Kumar Paul
Manash Kumar Paul
BBBharti Bisht
Bharti Bisht
DBDeblina Basu
Deblina Basu
SMSubhadip Mukhopadhyay
Subhadip Mukhopadhyay

1 June 2026 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ELElaine Y. Lin
Elaine Y. Lin
SMSubhadip Mukhopadhyay
Subhadip Mukhopadhyay
DCDeborah Corcoran
Deborah Corcoran
Mohamad AssiMohamad Assi
Mohamad Assi
JRJoel Encarnación Rosado
Joel Encarnación Rosado
AKAlec C. Kimmelman
Alec C. Kimmelman
Pancreatic ductal adenocarcinoma (PDAC) relies on elevated autophagy to support metabolism, proliferation, and immune evasion. Inhibiting autophagy has been reported to improve response rates in patients with PDAC. In this work, we identified a mechanism to explain how loss of autophagy in PDAC triggers reprogramming of the tumor microenvironment (TME) to ultimately stimulate an antitumor response. Autophagy inhibition in PDAC recruited macrophages via the CXCL1/2-CXCR2 axis. Simultaneously, loss of autophagy resulted in a decrease of the canonical “don’t eat me” ligand CD47 on tumor cells, thereby inducing their susceptibility to macrophage phagocytosis. While CD8+ T cells were critical to the anti-tumor immune response to autophagy inhibition in PDAC, they were not directly involved in cytotoxicity but played a critical role in stimulating macrophage phagocytosis of tumor cells. Taken together, this study strongly supports the implementation of autophagy inhibition in pancreatic cancer and highlights a crucial link between PDAC biology and the TME-macrophage crosstalk that effectively promotes tumor cell killing.

18 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SKSravya Kankipati
Sravya Kankipati
Kanchan ShindeKanchan Shinde
Kanchan Shinde
MPManash K. Paul
Manash K. Paul
SMSubhadip Mukhopadhyay
Subhadip Mukhopadhyay
Cancer continues to be a primary cause of death globally, necessitating the constant development of effective and less toxic therapeutics. Cucurbitacins belong to the tetracyclic triterpenoids found mainly in the Cucurbitaceae family. Cucurbitaceae plants exert various biological activities such as anti-diabetic, anti-cancer and anti-inflammatory properties, which make them beneficial in addressing metabolic disorders. This review focuses on cucurbitacins namely A, B, C, D, E, I, IIa, which have been explored in cancer research. Cucurbitacins suppress tumor progression by activating cell death pathways, including apoptosis, autophagy, pyroptosis and ferroptosis. They are known to target multiple crucial biomolecular key players, such as STAT3, AKT, mTOR, ERK, EGFR and TLR4. Additionally, they disrupt cytoskeletal proteins and inhibit cell proliferation, invasion, migration, angiogenesis, and cell-cycle arrest. Cucurbitacins have been demonstrated to modulate tumor microenvironment, leading to enhanced host immune surveillance that reverses traditional therapy resistance from cisplatin, doxorubicin, and paclitaxel. In this review, we highlight the strong potential of cucurbitacins as anti-cancer agents, either as monotherapy or in combination, for the development of safer, cost-effective drugs with improved patient treatment outcomes.

1 January 2021
Verified
Book Chapter
Closed access
SMSubhadip Mukhopadhyay
Subhadip Mukhopadhyay
SBSujit Kumar Bhutia
Sujit Kumar Bhutia

14 August 2026
Verified
Other
Open access
ELElaine Y. Lin
Elaine Y. Lin
SMSubhadip Mukhopadhyay
Subhadip Mukhopadhyay
DCDeborah Corcoran
Deborah Corcoran
Mohamad AssiMohamad Assi
Mohamad Assi
JEJoel Encarnación-Rosado
Joel Encarnación-Rosado
AKAlec C. Kimmelman
Alec C. Kimmelman
The increase of macrophage infiltration in autophagy-inhibited PDAC tumors was independent from tumor sizes.